3 Reasons Growth Investors Will Love Novartis (NVS)

Core Viewpoint - The article highlights Novartis (NVS) as a recommended growth stock, emphasizing its strong earnings growth potential, efficient asset utilization, and positive sales growth outlook, supported by favorable earnings estimate revisions [2][10]. Earnings Growth - Novartis has a historical EPS growth rate of 7.9%, but the projected EPS growth for this year is 15.6%, surpassing the industry average of 14.8% [4]. Asset Utilization Ratio - The company's asset utilization ratio (sales-to-total-assets) is 0.52, indicating that Novartis generates $0.52 in sales for every dollar in assets, which is higher than the industry average of 0.47 [5]. Sales Growth - Novartis is expected to achieve a sales growth of 10.5% this year, compared to the industry average of 6.8% [6]. Earnings Estimate Revisions - The current-year earnings estimates for Novartis have been revised upward, with the Zacks Consensus Estimate increasing by 0.3% over the past month [8]. Overall Assessment - Novartis holds a Zacks Rank of 2 (Buy) and a Growth Score of B, indicating its potential as an outperformer and a solid choice for growth investors [10].